The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical implications of molecular alterations in intraductal carcinoma of the prostate.
 
Benjamin Miron
Stock and Other Ownership Interests - Guardant health
Consulting or Advisory Role - Intellisphere; Seattle Genetics/Astellas
 
Shuanzeng Wei
No Relationships to Disclose
 
Yasmine Baca
Employment - Caris Life Sciences
 
Daniel Herchenhorn
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen-Cilag; MSD Oncology
Research Funding - Pfizer (Inst)
 
Isabela Werneck Cunha
No Relationships to Disclose
 
Kevin Kayvan Zarrabi
Consulting or Advisory Role - Eisai
 
Jacqueline T Brown
Honoraria - Curio/Vaniam Group
Research Funding - Medicenna (Inst); Surface Oncology (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Curio/Vaniam Group
 
Matthew James Oberley
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
Travel, Accommodations, Expenses - Caris Life Sciences
 
Chadi Nabhan
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
 
Emmanuel S. Antonarakis
Honoraria - AIkido Pharma; Amgen; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Celgene (Inst); ClinicalMind; Clovis Oncology (Inst); Constellation Pharmaceuticals; Curium Pharma; Dendreon (Inst); ESSA; Exact Sciences; Foundation Medicine; GlaxoSmithKline; InVitae; ISMAR Health Care; Janssen Biotech; Lilly; Medivation; Merck; Orion; Sanofi; Tempus
Consulting or Advisory Role - AIkido Pharma; Amgen; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Clovis Oncology; Constellation Pharmaceuticals; Curium Pharma; Dendreon; ESSA; Exact Sciences; Foundation Medicine; GlaxoSmithKline; InVitae; ISMAR Health Care; Janssen Biotech; Lilly; Medivation; Merck; Orion; Sanofi; Tempus
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Celgene; Clovis Oncology; Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Daniel M. Geynisman
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Exelixis; Merck; Myovant Sciences; Pfizer; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); Calithera Biosciences (Inst); Genentech (Inst); Harpoon therapeutics (Inst); Merck (Inst)
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)